Synonyms: BMS986141 | compound 49 [PMID: 35729784]
Compound class:
Synthetic organic
Comment: BMS-986141 is an orally active, selective, and reversible protease-activated receptor 4 (PAR4) antagonist with antiplatelet/antithrombotic activity [1]. It was developed as a back-up to lead compound BMS-986120.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
BMS-986141 is a phase 2 clinical candidate that is designed to reduce the risk of thrombosis in coronary artery disease and stroke. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT02671461 | Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes" | Phase 2 Interventional | Bristol-Myers Squibb | ||
NCT05093790 | A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy Participants | Phase 2 Interventional | Bristol-Myers Squibb |